|Day Low/High||17.47 / 17.97|
|52 Wk Low/High||12.86 / 23.70|
Increased chance for company's sale presents activist campaign with a steeper climb.
Secures Formulary Status with Prime Therapeutics for Primary Care Medicines
Driving sector performance are a recent series of mergers and acquisitions, including Horizon Pharma's purchase of Raptor Pharmaceutical Corp. Then there's the political boost...
The pharmaceutical company is reportedly up for sale after being dogged by Starboard Value for months, and could go for up to $41 million.
The buyer's CEO said it will look at both large acquisitions and Phase 2 and pre-approved assets in the wake of the $800 million purchase of the maker of Procysbi.
Horizon Pharma's (HZNP) stock price target was lifted at Brean Capital on Tuesday after the company agreed to buy Raptor Pharmaceuticals (RPTP).
Relief floods Wall Street on Monday after a number of Federal Reserve speakers take a dovish turn following increasingly hawkish rhetoric coming out of the central bank.
Relief flooded Wall Street after a number of Fed speakers took a dovish turn following increasingly hawkish rhetoric.
Here's a technical look at how to trade some of the most active stocks on the market right now.
Stocks rise Monday after Federal Reserve Gov. Lael Brainard urges 'prudence' in raising rates.
Stocks pare gains on Monday as worries over how soon the Federal Reserve might hike interest rates keeps markets wary.
Stock futures moved sharply lower on Monday morning, extending Friday's selloff, as worries continued over how soon the Federal Reserve might hike interest rates.
Horizon says the $800 million offer will bolster its rare disease business and its operations outside the U.S..
Citi said in a note Friday that Horizon Pharma (HZNP) could be hurt by Democratic presidential candidate Hillary Clinton's new drug plan.
Cramer says CyberArk Software is doing well but he's avoiding Clovis Oncology.
Cramer says he doesn't understand the obsession some investors have with the Federal Reserve. Forget the Fed.
Before Monday's opening bell, Horizon Pharma (HZNP) reported earnings that topped analysts' expectations for the 2016 second quarter.
Trade-Ideas LLC identified Horizon Pharma (HZNP) as a "water-logged and getting wetter" (weak stocks crossing below support with today's range greater than 200%) candidate
Horizon Pharma (HZNP) stock is advancing on Monday morning as Morgan Stanley raised its rating on shares to ‘equal weight’ from ‘underweight.’
Here are Monday's top research calls, including an upgrade for GameStop, and downgrades for Baker Hughes, ConocoPhillips and Toll Brothers.